01—Abstract
Summary
Summary of the 10-Q filed November 4, 2026. Cited figures are marked; the original filing is the authoritative source.
Abbott Laboratories reported a significant increase in net sales for the nine months ended September 30, 2026, driven primarily by the strategic acquisition of Exact Sciences completed in March 2026.
This acquisition has bolstered Abbott's presence in the cancer diagnostics market, contributing substantially to the Diagnostic Products segment's revenue growth. Despite a strong top-line performance, the company experienced a decrease in net earnings and earnings per share for both the three and nine-month periods compared to the prior year. This decline is largely attributable to increased operating expenses, including higher amortization costs stemming from the Exact Sciences acquisition, increased interest expense due to new debt financing, and charges related to significant legal settlements.
Investors should monitor the integration progress of Exact Sciences and the impact of ongoing legal matters on future profitability. The company also announced its intention to separate its Nutrition business into an independent entity, a move expected to be completed by the end of 2027, which could reshape Abbott's future operational focus and financial profile.
02—Key points
Key Highlights
- Net sales increased by 14.5% (14.8% excluding foreign exchange) for the three months ended September 30, 2026, and by 11.9% (10.5% excluding foreign exchange) for the nine months ended September 30, 2026, largely driven by the acquisition of Exact Sciences.
- The Diagnostic Products segment saw substantial growth, with a 46.7% increase in sales for the quarter and 32.4% for the nine months (excluding foreign exchange), primarily due to the inclusion of Exact Sciences' revenue.
- Net earnings decreased to $920 million ($0.53 per diluted share) for the third quarter of 2026 from $1.644 billion ($0.94 per diluted share) in the prior year, and to $2.925 billion ($1.67 per diluted share) for the nine months from $4.748 billion ($2.70 per diluted share) in the prior year.
- Operating earnings decreased to $1.358 billion for the third quarter and $4.396 billion for the nine months, compared to $2.057 billion and $5.802 billion in the prior year periods, respectively, impacted by higher operating costs and expenses.
- The company incurred significant expenses related to legal settlements, including a $670 million charge for NEC claims and a $385 million payment to resolve DOJ investigations regarding infant formula manufacturing.
- Abbott announced its intention to separate its Nutrition business into an independent, publicly traded company, with completion expected by the end of 2027.
- Cash and cash equivalents decreased significantly from $8.5 billion at the end of 2025 to $4.1 billion at September 30, 2026, mainly due to funding the Exact Sciences acquisition and related debt repayment.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2026, Abbott Laboratories kept $0.07.
- Revenue$13.01B100.0%
- Cost of revenue−$5.63B43.2%
- Gross profit$7.38B56.8%
- Operating costs−$6.03B46.3%
- Operating income$1.36B10.4%
- Interest, other & tax−$438.0M3.4%
- Net income$920.0M7.1%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2026filed November 4, 2026Financial Statements
Q3 FY2026 against Q3 FY2025
| Line item | Q3 FY2026Q3 FY2025 | Change |
|---|---|---|
| Revenue | $13.01B$11.37B | +14.5% |
| Cost of Revenue | $5.63B$5.08B | +10.9% |
| Gross Profit | $7.38B$6.29B | +17.3% |
| R&D Expenses | $920.00M$766.00M | +20.1% |
| SG&A Expenses | $4.27B$3.05B | +39.8% |
| Operating Expenses | $11.65B$9.31B | +25.2% |
| Operating Income | $1.36B$2.06B | −34.0% |
| Net Income | $920.00M$1.64B | −44.0% |
| EPS (Basic) | $0.53$0.94 | −43.6% |
| EPS (Diluted) | $0.53$0.94 | −43.6% |
| Shares Outstanding (Basic) | 1.73B1.74B | −0.4% |
| Shares Outstanding (Diluted) | 1.74B1.75B | −0.7% |
05—Questions
Frequently Asked Questions
What was the primary driver of Abbott's revenue growth in this period?
The primary driver of Abbott's revenue growth was the acquisition of Exact Sciences Corporation, which was completed on March 23, 2026. This acquisition significantly boosted the Diagnostic Products segment, particularly within the new Cancer Diagnostics business.
Why did net earnings decrease despite strong sales growth?
Net earnings decreased due to several factors, including significantly higher operating costs and expenses. These include increased amortization of intangible assets related to the Exact Sciences acquisition, higher interest expense from new debt financing, and substantial charges for legal settlements. These factors outweighed the revenue gains.
What is the significance of the planned separation of the Nutrition business?
Abbott announced its intention to separate its Nutrition business into an independent company. This strategic move aims to allow each business (healthcare devices/diagnostics/pharma and nutrition) to focus on its specific growth opportunities and markets. Investors should watch for details on the structure, timing, and potential financial implications of this separation, which is expected to be completed by the end of 2027.
What are the key legal and financial risks highlighted in this report?
Key risks include ongoing litigation related to NEC claims (resulting in a $670 million charge) and a $385 million settlement for infant formula manufacturing investigations. The company also faces significant IRS tax assessments for multiple years, which are being contested in Tax Court. Furthermore, the substantial increase in long-term debt to finance the Exact Sciences acquisition impacts interest expenses and liquidity.
06—Continue